Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
Carlsson S, Barata P, Bryce A, George D, Gillessen S, Loeb S, Montgomery B, Morris D, Riaz I, Palapattu G, Schoen M, Washington Iii S, Cornell B, Levine R, Aggarwal P, McGowan T, Cotter M, Thompson B, Devgan G, Russell D, Kuperman G, Lenero E, Iwata K, Miyahira A, Soule H, Carithers G, Oh W, Agarwal N. Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer. JCO Oncology Practice 2025, op2500050. PMID: 40315399, DOI: 10.1200/op-25-00050.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerProstate Cancer FoundationHormone-sensitive prostate cancerCombination therapyProstate cancerPatients treated with combination therapyAndrogen receptor pathway inhibitorsBenefit of combination therapyQuality of lifeSignificant survival improvementUrban-dwelling patientsPreserving quality of lifeEnhanced survival outcomesGuideline-concordant careMeta-analysesRandomized Controlled TrialsDeprivation therapyEvidence-based therapiesSurvival outcomesTreatment utilization patternsSurvival improvementClinical trialsGlobal RegistryPathway inhibitorCombined treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply